Clinical and Cost-Saving Effects of the Drug Utilization Review Modernization Project in Inpatient and Outpatient Settings in Korea.
Journal
Journal of patient safety
ISSN: 1549-8425
Titre abrégé: J Patient Saf
Pays: United States
ID NLM: 101233393
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
20
5
2022
medline:
24
8
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
Korea's national health insurance authority introduced a drug utilization review modernization pilot project in which health professionals provided follow-up services to monitor adverse drug events. We aimed to evaluate the effects of the project on clinical and economic outcomes. We conducted difference-in-differences analysis using National Health Insurance claims data from the Health Insurance Review and Assessment Service. We calculated the number of adverse drug events and allergic reactions as a clinical indicator and medical costs incurred to manage these events as an economic indicator. Absolute difference in each outcome measure was defined as the value after the project minus the value before the project. Difference-in-differences was defined as a difference in absolute differences between the intervention group and the control group. Overall, difference-in-differences were -43 and -826 for the number of drug-related adverse events and allergic reactions and -$198,700 and $53,318 for medical costs in the inpatient and outpatient settings, respectively. For outpatients, the monthly number of adverse drug events and allergic reactions has grown higher for the control group than for the intervention group after implementation of the pilot project. Implementation of the pilot project lowered the number of adverse drug events and allergic reactions in the inpatient and outpatient setting. The project also lowered medical costs incurred to manage these events in the inpatient setting only. Based on our findings, we recommend that the pilot project be expanded on a nationwide level at least in the inpatient setting.
Identifiants
pubmed: 35587895
doi: 10.1097/PTS.0000000000001030
pii: 01209203-202209000-00013
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-610Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors disclose no conflict of interest.
Références
Stausberg J, Hasford J. Identification of adverse drug events: the use of ICD-10 coded diagnoses in routine hospital data. Dtsch Arztebl Int . 2010;107:23–29.
Nebeker JR, Hoffman JM, Weir CR, et al. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med . 2005;165:1111–1116.
Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. JMCP . 2010;16:185–195.
Hatah E, Tordoff J, Duffull SB, et al. Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. Int J Clin Pharmacol . 2014;36:503–512.
Stewart D, Whittlesea C, Dhital R, et al. Community pharmacist led medication reviews in the UK: a scoping review of the medicines use review and the new medicine service literatures. Res Social Adm Pharm . 2020;16:111–122.
Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol . 2012;74:573–580.
Latif A. Community pharmacy Medicines Use Review: current challenges. Integr Pharm Res Pract . 2017;7:83–92.
Burns A. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc . 2008;48:341–353.
Kim SJ, Han KT, Kang HG, et al. Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea. Public Health . 2018;163:128–136.
Jung SY, Jang EJ, Choi S, et al. Effect of a nationwide real-time drug utilization review system on duplicated nonsteroidal antiinflammatory drug prescriptions in Korea. Arthritis Care Res . 2020;72:1374–1382.
Lee J, Noh Y, Lee S. Evaluation of preventable adverse drug reactions by implementation of the nationwide network of prospective drug utilization review program in Korea. PLoS One . 2018;13:e0195434.
Health Insurance Review and Assessment Service. Press release—DUR modernization pilot project to start in August. Published July 31, 2019. Available at: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&brdScnBltNo=4&brdBltNo=9859 . Accessed March 3, 2020.
Kim HK, Song SO, Noh J, et al. Data configuration and publication trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database. Diabetes Metab J . 2020;44:671–678.
Hohl CM, Karpov A, Reddekopp L, et al. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc . 2014;21:547–557.
Saff RR, Li Y, Santhanakrishnan N, et al. Identification of inpatient allergic drug reactions using ICD-9-CM codes. J Allergy Clin Immunol Pract . 2019;7:259–264.e1.
Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA . 2014;312:2401–2402.
Kolhatkar A, Cheng L, Chan FKI, et al. The impact of medication reviews by community pharmacists. J Am Pharm Assoc . 2016;56:513–520.e1.
Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med . 2015;175:76–87.
Peng CC, Glassman PA, Marks IR, et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. JMCP . 2003;9:513–522.
Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med . 2006;166:565–571.
Lapointe-Shaw L, Bell CM, Austin PC, et al. Community pharmacy medication review, death and re-admission after hospital discharge: a propensity score–matched cohort study. BMJ Qual Saf . 2020;29:41–51.
Brummel A, Lustig A, Westrich K, et al. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management. JMCP . 2014;20:1152–1158.
Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc . 2008;48:203–214.
Malet-Larrea A, Goyenechea E, García-Cárdenas V, et al. The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients. Br J Clin Pharmacol . 2016;82:831–838.
Lee H, Choi HS, Ji E. The effects after implementing a drug utilization review system on contraindicated drug use: a systematic review. Korean J Clin Pharm . 2019;29:9–17.